ONC201 shows promise in AML treatment

Holly EdwardsDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI;Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI

Yubin GeDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI;Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI;Department of Pediatrics, Wayne State University School of Medicine, Detroit, MICorrespondence[email protected]

References

Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol 2017;18:17. doi:10.1007/s11864-017-0456-2. PMID:28286924
PubMed Web of Science ®Google Scholar
Ho TC, LaMere M, Stevens BM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood 2016;128:1671–1678. doi:10.1182/blood-2016-02-695312. PMID:27421961
PubMed Web of Science ®Google Scholar
Stein MN, Bertino JR, Kaufman HL, et al. First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res 2017;23:4163–4169. doi:10.1158/1078-0432.CCR-16-2658. PMID:28331050
PubMed Web of Science ®Google Scholar
Arrillaga-Romany I, Chi AS, Allen JE, et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017;8:79298–79304. PMID:29108308
PubMed Web of Science ®Google Scholar
Allen JE, Krigsfeld G, Mayes PA, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013;5:171–117. doi:10.1126/scitranslmed.3004828. PMID:23390247
PubMed Web of Science ®Google Scholar
Prabhu VV, Talekar MK, Lulla AR, et al. Single agent and synergistic combniatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle 2017. doi:10.1080/15384101.2017.1403689.
PubMed Web of Science ®Google Scholar
Ishizawa J, Kojima K, Chachad D, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 2016;9:17. doi:10.1126/scisignal.aac4380. PMID:26884599
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

ONC201 shows promise in AML treatment

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

ONC201 shows promise in AML treatment

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date